Oropharyngeal squamous cell carcinoma (OPSCC) was historically treated with primary open surgery. Cure rates were low; complication rates were high; and patient health-related quality of life (HRQOL) decreased. In an effort to at least minimize morbidity, a quest for organ preservation protocols was undertaken,
1-3 and treatment paradigms shifted toward primary external-beam radiation therapy (XRT) or chemoradiation therapy (CRT). Unfortunately, these protocols failed to provide desired solutions because they were often associated with significant acute and chronic toxic effects.
4-6 The result was impaired upper aerodigestive tract function and suboptimal HRQOL.
7,8 Therefore, head and neck surgeons are still seeking the ultimate balance between cancer cure, functional outcomes, minimal morbidity, and HRQOL.